N/A N=6,049

Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique

COVID-19

Bottom Line

View on ClinicalTrials.gov: NCT04442165 ↗

Enrolled (actual)

6,049

Serious AEs

—

Results posted

Jan 2025

Primary outcome: Primary: COVID-19 Disease Incidence Rate (Symptomatic Infections Per Month) — 364.5 infections per 1000 person-years

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Institute of Tropical Medicine, Belgium
Primary completion: Mar 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY COVID-19 Disease Incidence Rate (Symptomatic Infections Per Month)	364.5	—
PRIMARY COVID-19 Related Hospitalization Rate Due to SARS-CoV-2	—	—
PRIMARY Case (Disease) Fatality Risk (Percent) Due to SARS-CoV-2	1	—
PRIMARY Percentage Asymptomatic Infections	86.6	—
PRIMARY Percentagge of Participants With SARS-CoV-2 Infection Annually	4.8; 34.7	—

Summary

A population-based COVID19 surveillance in a household cohort will be set-up using an existing Household demographic surveillance system (HDSS). From any individual in this population with any respiratory symptom or loss of smell or taste, with or without fever, investigators will collect a respiratory specimen and test these for SARS-CoV-2 virus, during 12 months. Demographic, epidemiological and clinical data of possible cases and of the source population will be recorded at baseline. An age-stratified serial sero-survey will be conducted at baseline in a subset of the population in the population-based COVID19 surveillance, and at 3, 6 and 12 months, after confirmation of community transmission.

Eligibility Criteria

Inclusion Criteria

Any individual enrolled in the Polana Caniço-HDSS: All members residing in the household for at least 3 months (infants, children, adults, elderly), regardless of age, underlying conditions, medical history, infection or disease status or history
Able and willing to provide written informed consent: by the household head for the surveillance; by each selected participant for the sero-survey.

No Exclusion Criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04442165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.